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Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but life-
threatening adverse drug reaction. Several criteria have been established to aid the diagnosis. Howev-
er, patients with DRESS remained underdiagnosis and undertreatment.
Methods: Medical records of hospitalized patients at the King Chulalongkorn Memorial Hospital from
January 2004eDecember 2014 due to DRESS were enrolled retrospectively using RegiSCAR diagnostic
criteria.
Results: A total of 52 patients were included. Thirty-seven patients (71.2%) were female. The four most
common causative agents were phenytoin (23.1%), nevirapine (17.3%), allopurinol (15.4%), and cotri-
moxazole (13.5%). The overall prevalence was 9.63 cases per 100,000 inpatients. Median onset time (IQR)
was 16 (9e27) days. Allopurinol was associated with longer onset time than others (p ¼ 0.014). Clinical
presentation: skin rash 100%, fever 78.8%, and lymphadenopathy 50%. The majority (84.6%) had single
internal organ involvement. The most common internal organ involvement was liver (94.2%). Allopurinol
was associated with higher incidence of renal involvement (p ¼ 0.01). Up to 60% of patients had
eosinophilia. Allopurinol was associated with higher eosinophilia (p ¼ 0.003). A half of patients received
systemic corticosteroids. Two mortality cases were reported (omeprazole-fulminant hepatitis and
phenytoin-nosocomial infection).
Conclusions: DRESS is associated with severe morbidity and mortality. Phenytoin, nevirapine, allopurinol,
and cotrimoxazole were the major causes. Allopurinol-induced DRESS had the longest onset time, and
was associated with higher eosinophilia and incidence of renal involvement. Raising awareness among
both health care providers and public for early detection and withdrawal of the causative agent is critical
to save life and reduce morbidity.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ical Immunology, Department
University, Bangkok, 10330
).
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Drug reaction with eosinophilia and systemic symptoms
(DRESS) is a rare but severe adverse drug reaction characterized by
fever, cutaneous eruption, and involvement of one or more internal
organs. Although it was ﬁrst introduced by Bocquet et al. in 1996,1
the term DRESS is still inconsistent due to its variable clinicalvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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the diagnosis challenging. Moreover, there are several nomencla-
tures for this syndrome such as drug hypersensitivity syndrome,
drug-induced delayed multiorgan hypersensitivity syndrome, and
drug-induced hypersensitivity syndrome, making diagnosis of
DRESS more confusing.2e4 In Asia, DRESS was reported to almost
one tenth of adverse drug reaction cases, with a mortality rate
ranged 3e10%.5e8 Mortality cases were mainly caused by multiple
organ failure and sepsis. Various medications have been described
to be the cause of DRESS. Phenytoin and allopurinol were twomost
commonly reported culprit drugs.5e8
The objectives of this study are to evaluate and describe the
causative agents, severity, and the clinical course of patients with
DRESS hospitalized at an Asian tertiary care setting.Table 1
Demographic characteristics.
No. (%)
Sex (n, %)
Female:Male 37 (71.2):15 (28.8)
Median age (IQR) years 33 (25.3e53.3)
Median hospital stay (IQR) days 7 (5e9)Methods
This study is a descriptive retrospective study of hospitalized
patients at the King Chulalongkorn Memorial Hospital between
January 2004 and December 2014 due to DRESS. Using the elec-
tronic database of Faculty of Medicine, Chulalongkorn University,
we were able to recruit the target patients. Because there is
currently no ICD10 speciﬁcally used for DRESS, L27.0 (generalized
skin eruption due to drugs and medicaments) and T88.7 (unspec-
iﬁed adverse effect of drug or medicament) were used. All medical
records, including those whom DRESS were not the initial diag-
nosis, were then further reviewed to identify patients fulﬁlling the
diagnostic criteria of DRESS.
The diagnostic criteria used in this study were purposed by
European Registry of Severe Cutaneous Adverse Reactions (RegiS-
CAR).9 Hospitalization and reaction suspected to be drug related
were mandatory for diagnosis. Also, 3 out of the following 7 criteria
were needed to fulﬁll the diagnosis: acute skin rash, fever above
38 C, enlarged lymph node at 2 or more sites, involved at least 1
internal organ, lymphocyte count above or below laboratory limits,
eosinophil count above laboratory limits, and platelet count below
laboratory limits. Patients who corresponded to the RegiSCAR
criteria were then further evaluated using scoring system for clas-
sifying cases as deﬁnite, probable, possible, or no case. Only deﬁ-
nite, probable, and possible cases were included for further
analysis.
As for culprit drugs, a modiﬁcation to that of WHOeUMC cau-
sality categories was applied to identify the culprit drug.10 Classi-
ﬁcation of culprit drugs in this study were deﬁnite reaction (proven
by challenge or provocative test), probable reaction (improving by
withdrawing only the culprit drug or had taken only culprit drug0
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Fig. 1. Yearly prevalence of DRESS in the King Chulalongkorn Memorial Hospital,
Bangkok, Thailand during 2004e2014.before presentation), and possible reaction (improving by with-
drawing multiple drugs, including the suspected culprit drug or
had taken multiple medication but the culprit drug was suspected
because of its incidence).
The statistical analyses used for evaluation of the signiﬁcance of
differences in this study were ManneWhitney U Test for contin-
uous variables and Chi-square for categorical variables. A value of
p < 0.05 was regarded as signiﬁcance.
Results
Of 540,099 admissions to the King Chulalongkorn Memorial
Hospital between January 2004 and December 2014, ﬁfty-two pa-
tients were included. The yearly prevalence is shown in Figure 1.
The overall prevalence during 11 years period was 9.63 cases per
100,000 inpatients. The highest prevalence was in 2004 (18.6 cases
per 100,000 inpatients).
A total of 52 patients were included in this study. Using RegiS-
CAR scoring system, 28 patients were classiﬁed as possible case, 18
patients as probable case, and 6 patients as deﬁnite case. A sum-
mary of the demographic and baseline characteristics are shown in
Table 1. Therewere 15male and 37 female patients, giving a male to
female ratio of 1:2.47. The age group ranged from 2 to 86 years
(median age 33 years). Allopurinol-induced DRESS was associated
with older age group (p < 0.001). The median onset time (IQR) was
16 (9e27) days. Allopurinol was associated with longer onset time,
median (IQR) of 30 days (20.3e40.8) (p ¼ 0.014). The period of
hospitalization ranged from 2 to 54 days, with a median (IQR) of 7
(5e9) days.
Eight patients (15.4%) had previous history of drug allergy. All
drugs were different from the culprit drug responsible for this
hospitalization.
The most common causative drug was phenytoin (23.1%). Other
common causes were nevirapine, allopurinol, and cotrimoxazole
(17.3%, 15.4%, and 13.5%, respectively) (Fig. 2). Of noted, half of the
causative drugs were anti-infectious agents.
The most common underlying disease was HIV infection
(28.8%), all of whom had reported anti-infectious agents as theMedian onset (IQR) days 16 (9e27)
Initial diagnosis (n, %)
Drug reaction with eosinophilia and
systemic symptoms (DRESS)
28 (53.8)
Drug-induced hypersensitivity
syndrome (DIHS)
14 (26.9)
Drug hypersensitivity 6 (11.5)
Drug allergy 4 (7.7)
Case classiﬁcation according to RegiSCAR score
Deﬁnite (score >5) 6 (11.5)
Probable (score 4e5) 18 (34.6)
Possible (score 2e3) 28 (53.8)
History of drug allergy (n, %) 8 (15.4)
Underlying disease (n, %) 42 (80.8)
HIV 15 (28.8)
Convulsion disorder 12 (23.1)
Hypertension 13 (25.0)
Dyslipidemia 9 (17.3)
Diabetes mellitus 8 (15.4)
Hyperuricemia 8 (15.4)
Chronic kidney disease 4 (7.7)
Others 13 (25.0)
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Fig. 2. Summary of culprit drugs of DRESS in this study.
Table 3
Clinical characteristics.
No. (%)
Fever 41 (78.8)
Lymphadenopathy 26 (50.0)
Skin rash 52 (100)
Extent of rash > 50% 23 (44.2)
Maculopapular rash 49 (94.2)
Bullous 1 (1.9)
Wheal & ﬂare 1 (1.9)
Plaque 2 (3.8)
Patch 2 (3.8)
Target lesion 2 (3.8)
Facial edema 4 (7.7)
Periorbital edema 3 (5.8)
Conjunctival injection 4 (7.7)
Abdominal pain 3 (5.8)
Diarrhea 4 (7.7)
Hepatomegaly 18 (34.6)
Splenomegaly 1 (1.9)
Internal organ involvement
1 organ involved 44 (84.6)
2 or more organs involved 8 (15.4)
Liver 49 (94.2)
Median alanine aminotransferase
level IU/L (IQR)
333 (215e690)
Kidney 8 (15.4)
Lung 2 (3.8)
Other 1 (1.9)
Hematologic abnormalities
Eosinophilia 30 (57.7)
Median % Eosinophil (IQR) 18.1 (12.9e22.9)
Median absolute eosinophil/mL (IQR) 1,482 (856.7e3,652.2)
Atypical lymphocyte 14 (26.9)
Median % atypical lymphocyte (IQR) 10 (6e20.5)
Lymphocytosis 14 (26.9)
Median lymphocyte count/mL (IQR) 9,154 (6,024e15,594)
Lymphopenia 27 (51.9)
Median lymphocyte count/mL (IQR) 680 (456e1,058)
Thrombocytopenia 13 (25)
Median platelet count/mL (IQR) 84,000 (53,000e111,000)
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infectious agents reported to be culprit drugs and the underlying
disease of HIV infection.
A summary of clinical characteristic is shown in Table 3. All
patients presented with rash, almost all were maculopapular type
(94.2%). Other common skin rashes included plaque, patch, and
target lesions. Seven patients also reported to have either facial
edema or periorbital edema. Conjunctival injectionwas reported in
4 patients. Fever, lymphadenopathy, and hepatomegaly were the
other common clinical ﬁndings (78.8%, 50.0, and 34.6%, respec-
tively). Majority of lymphadenopathy involved cervical lymph
nodes. Gastrointestinal symptoms were also reported in 7 patients.
Forty-four patients (84.6%) had single internal organ involve-
ment, while others had two or more internal organ involvements.
Of 8 patients who had two organ internal organ involvements, 6
patients had a combination of liver and kidney involvement. Liver
was the most common internal organ involved, accounted for
94.2%. Median level (IQR) of alanine aminotransferase (ALT) was
333 (215e690) IU/L. The kinetic of ALT level of the 4 most common
causative drugs were shown in Figure 3. Nevirapine-induced DRESS
was associated with signiﬁcant increase of ALT level during the ﬁrst
2 weeks of onset of symptoms compared to the others (p ¼ 0.005).
Eight patients (15.4%) had kidney involvement. All kidney
involvement were acute kidney injury (AKI), with 2 of those re-
ported to have AKI on-top chronic kidney disease (CKD).
Allopurinol-induced DRESS was associated with higher incidence
of renal involvement (62.5% versus 6.8% of allopurinol versus non-
allopurinol, respectively, p ¼ 0.01). Two patients had pneumonitis
and one patient had splenomegaly.
Eosinophilia was reported in 30 patients (57.7%), with a median
% eosinophil (IQR) of 18.1% (12.9e22.9) and a median absolute
eosinophil count (IQR) of 1,482 (856.7e3,652.2) cells/mL. BothTable 2
Relationship between all anti-infectious agents reported to be culprit drugs and
underlying disease of HIV infection. Half the culprit drugs were anti-infectious
agents. All patients with underlying HIV infection had anti-infectious agents as
their culprit drugs.
Culprit drugs Overall n ¼ 26 Known HIV infection
Yes n ¼ 15 No n ¼ 11
Ciproﬂoxacin 1 e 1
Clindamycin 1 e 1
Cotrimoxazole 7 4 3
Dapsone 4 e 4
Isoniazid 3 1 2
Nevirapine 9 9 e
Sulfadiazine 1 1 emedian % eosinophil and median absolute eosinophil were higher
in patient whom allopurinol was the culprit drug (p ¼ 0.009 and
p ¼ 0.003, respectively) (Table 4). Fourteen patients (26.9%) had
atypical lymphocyte, with a median % atypical lymphocyte (IQR) of
10% (6e20.5). Thirteen patients (25%) had thrombocytopenia, with
a median platelet count (IQR) of 84,000 (53,000e111,000) cells/mL.
Lymphopenia was also reported in approximately a half the pa-
tients (51.9%). Blood test for human herpesvirus 6 (HHV-6) was
performed in 6 patients. The results were positive for serum IgG
antibody and negative for serum IgM antibody in 4 patients. No
further quantitative test was done. The results for 2 remaining
patients were unavailable.
The culprit drug was discontinued in every patient. Up to 85%,
the culprit drug was discontinued in the ﬁrst day of admission. The
longest duration until discontinuation was 11 days (phenytoin was
the culprit drug, this case was fortunately survived). Systemic
corticosteroid, either intravenous dexamethasone or oral prednis-
olone, was administered to 30 patients (57.7%). Forty-nine patients
(94.2%) received antihistamine, either chlorpheniramine or hy-
droxyzine (Table 5). However, when evaluated only in those who
initial diagnosis were DRESS, systemic corticosteroid was admin-
istered in 23 out of 28 patients (82.1% versus 29.2% of whom initial
diagnosis were DRESS versus other initial diagnosis, respectively,
p < 0.001). There was no different in lag time of systemic cortico-
steroid administration between the 2 groups.
Two patients died during admission. One died from DRESS-
related fulminant liver failure and the other was from nosocomial
infection. The culprit drugs were omeprazole and phenytoin,
respectively.
Fig. 3. The kinetic change of mean with standard error (SE) of ALT level since the onset of DRESS by the 4 most common culprit drugs. , the median day of culprit drug withdrawal
since onset of symptoms. NA, not available. Nevirapine was associated with signiﬁcant increase of ALT level during the ﬁrst 2 weeks of onset of symptoms compared to the others
(p ¼ 0.005).
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Drug reaction with eosinophilia and systemic symptoms
(DRESS) is a rare but severe adverse drug reaction, with broadTable 4
Comparison between 4 most common culprit drugs and others.
Features Allopurinol n ¼ 8 p valuey Cotrimoxazole
Age, median (IQR), y 75 (56.5e78.8) <0.001* 33 (21e39)
Hospitalization, median (IQR), d 6 (5.3e15.3) 0.813 7 (5e7)
Onset, median (IQR), d 30 (20.3e40.8) 0.014* 21 (10e24)
Median days from onset of
symptom to culprit drug
withdrawal (IQR)
9 (6e18.8) 0.195 5.5 (2.8e6.3)
%Eosinophil, median (IQR) 21.4 (14.4e32) 0.009* 8 (5.5e19.7)
Absolute eosinophil count,
median (IQR), cells/mL
3,192.4 (1,117.9e7,093.1) 0.003* 960 (431.2e1,7
ALT, median (IQR), IU/L 141 (109.5e748.3) 0.108 332 (271)
Eosinophilia, Y (%) 7 (87.5) 0.12 5 (71.4)
Renal involvement, Y (%) 5 (62.5) 0.01* 1 (14.3)
ALT, Alanine aminotransferase; d, day; y, year; Y, yes.
*Statistically signiﬁcant, when p < 0.05.
y Allopurinol group vs others.
z Cotrimoxazole group vs others.
x Nevirapine group vs others.
¶ Phenytoin group vs others.clinical features. The estimated incidence of DRESS ranges from 1 in
1,000 to 1 in 10,000 drug exposures. A recent study in Europe re-
ported an overall prevalence of 37.6 cases per 100,000 inpatients.11
Multiple factors have been described to associate with DRESSn ¼ 7 p valuez Nevirapine n ¼ 9 p valuex Phenytoin n ¼ 12 p value¶
0.528 30 (26.5e41.5) 0.537 34.5 (27.5e45) 0.948
0.545 5 (3e9.5) 0.146 10 (5.3e13) 0.072
0.733 14 (5.5e14.5) 0.064 16 (8.5e29.5) 0.991
0.127 13 (7.5e14) 0.031* 5.5 (3.3e9) 0.192
0.599 8.5 (2e14.5) 0.282 15.2 (6.4e20) 0.35
02.1) 0.511 243.5 (84.8e863.2) 0.053 501.1 (192.6e2,920.2) 0.745
0.399 510 (346.5e717.5) 0.304 284.5 (217e386.5) 0.263
0.69 3 (33.3) 0.14 7 (58.3) 0.61
0.71 1 (11.1) 0.58 1 (8.3) 0.66
Table 5
Treatment received during hospitalization.
Overall
n ¼ 52
Initial diagnosis
DRESS n ¼ 28
Initial diagnosis
not DRESS n ¼ 24
p valuey
Systemic
corticosteroid (%)
30 (57.7) 23 (82.1) 7 (29.2) <0.001*
Antihistamine (%) 49 (94.2) 26 (92.9) 23 (95.8) >0.999
Topical
corticosteroid (%)
22 (42.3) 14 (50) 8 (33.3) 0.225
*Statistically signiﬁcant, when p < 0.05.
y Initial diagnosis DRESS vs Initial diagnosis not DRESS.
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cyte antigen-related gene, and HHV-6 reactivation.12,13 HHV-6 has
been deﬁned as a potential contributor to DRESS development.14,15
Uneven yearly prevalence of DRESS is seen in this study (Fig. 1).
During 11 years period, there were some trends regarding the
culprit drugs. The number of nevirapine-induced DRESS patients
contributed to approximately 50% of DRESS cases during 2004 and
2005. Interestingly, nevirapine was the second most common
culprit drugs in our study (17.3%) (Fig. 2). The result is uncommon
compared to previous reported worldwide (5%).16 Such ﬁnding
could be explained by higher prevalence of underlying HIV infec-
tion in our study and more frequent prescription of nevirapine in
Thailand in those years.17 Before 2010, nevirapine was the only
preferred NNRTI in HAART in Thailand. The number of nevirapine-
induced DRESS cases had declined since 2005, until the last case
reported in 2010, the same year when the Thailand's national
guideline for antiretroviral therapy recommended efavirenz as an
additional preferred NNRTI to nevirapine.18
The youngest patient in our study was a 2 years old girl diag-
nosed with carbamazepine-induced DRESS. Clinical presentations
were high-grade fever, rash, lymphadenopathy, eosinophilia, and
liver involvement. The onset time was 21 days and the patient
stayed at the hospital for 5 days, which were both shorter than a
case reported by EL omairi et al. on carbamazepine-induced DRESS
in a 6 years old boy patient (4 weeks and 2 weeks, respectively).19
On discharged, levetiracetam was given as a substitute with no
subsequent adverse reaction reported. There are few reports of
DRESS in children; and to our knowledge, our patient was among
the youngest patients diagnosed with DRESS.
Aromatic anticonvulsant was responsible for 28% of all cases in
our study. The most common culprit drug in our study was
phenytoin (23.1%) (Fig. 2). The ﬁnding is similar to other studies
which reported phenytoin and aromatic anticonvulsant to be the
most common culprit drugs.6,7,20,21 Notably, cross-reactivity is well
documented among aromatic anticonvulsant,12 thus avoidance of
re-expose to such medication should not be missed. There was no
history of potential aromatic cross-reactivity case in this study. Of
all 12 patients who was diagnosed phenytoin-induced DRESS,
phenytoin was switch to levetiracetam or valproic acid.
The third most common culprit drug in our study was allopu-
rinol (15.4%) (Fig. 2). The result is similar to some earlier reports.7,21
The ﬁnding can be described by high prevalence of HLA-B*5801 in
Thai population. HLA-B*5801 has known to be closely associated
with allopurinol-induced SCARs. Thus, recommendation of HLA-
B*5801 screening before initiating allopurinol has been purposed
as a risk management in select patient subpopulations with
elevated risk, including Thai descent.22,23 Another reason contrib-
uted to such ﬁnding is allopurinol can be bought as an over-the-
counter drug in Thailand, thus the patients might not be aware of
its potential side effects. Allopurinol was also associated with
DRESS in older age group (p < 0.001). Higher accumulation of
oxypurinol, an active metabolite of allopurinol, in geriatric patients
resulted from declined renal function may be contributed to suchﬁnding.24,25 In contrast to nevirapine, allopurinol-induced DRESS
was ﬁrst reported later in 2009 and increased during 2013 and
2014. The reason is unclear.
Half of the culprit drugs in our study were anti-infectious agents
(Table 2). Fifteen of those had underlying HIV infection (Table 1).
Therefore, the ﬁnding of high percentage of anti-infectious agent as
the cause for DRESS in this study could be due to high proportion of
patients with underlying HIV infection in our study.5,7
The median onset time, Table 1 and 4, in our study was com-
parable to the 22 days observed in the RegiSCAR study.21 Similar to
previous reports, allopurinol-induced DRESS was associated with
longer onset time (p ¼ 0.014).7 Patients with allopurinol-induced
DRESS had a median onset of 30 days, which is comparable to 3
weeks reported in a large systemic review of allopurinol
hypersensitivity.26
All patients presented with rash (Table 3). Maculopapular rash
was the most common feature (94.2%). Six patients have more than
one feature of rashes. The histopathological feature of DRESS is
poorly characterized. Presence of superﬁcial perivascular lympho-
cytic inﬁltrate, extravasation of erythrocytes, necrotic keratino-
cytes, and, less frequently, dermal eosinophils were some of the
patterns reported.27 In our study, skin biopsywas done in 4 patients
which showed perivascular lymphocytic inﬁltration, similar to
previous reports.5,7,28
Proportion of patients with liver involvement, Table 3 and
Figure 3, were similar to other reports from Asia, but were much
higher compared to result from European studies.5,21,29,30 There
was no signiﬁcant difference between the levels of ALT of each
culprit drugs. However, becausewewere able to record and analyze
the kinetics of the ALT level in 4 most common culprit drugs, we
found a signiﬁcant difference in kinetic change of ALT level in pa-
tients with nevirapine-induced DRESS during the ﬁrst 2 weeks of
onset of symptoms compared to the other 3 culprit drugs
(p ¼ 0.005). The longer period between onset of symptom and
withdrawal of culprit drug could be the factor contributed to such
result (p ¼ 0.031). Also, the ﬁnding could be described by high
prevalence of HLA*B35 in Thai population, which associated with
nevirapine-induced hepatotoxicity.31,32 Closed monitoring of
transaminase during the ﬁrst 12 week of nevirapine-containing has
been recommended.33 All patients with nevirapine-induced DRESS
did not received systemic corticosteroid, thus the role of systemic
corticosteroid towards nevirapine-induced hepatotoxicity is
inconclusive in this study. However, the result suggests that with-
drawal of nevirapine should rapidly prevent further elevation of
abnormal ALT level.
The proportion of patients with renal involvement was similar
to previous reports (16e53%).7,21,34 Five out of eight patients who
had renal involvement were caused by allopurinol, which repre-
sents 62.5% of patients whom allopurinol was the culprit drug
(Table 4). The similar ratio of allopurinol-induced DRESS patients
who have to those who don't have renal involvement was also re-
ported (68.4%).5
Previous studies from both Asia and Europe showed varied
number of patients with eosinophilia, ranging from 48 to 95%.7,21,34
Despite dissociation between culprit drugs and presentation with
eosinophilia, allopurinol was associated with signiﬁcant higher
eosinophil level compared to other culprit drugs (p ¼ 0.003).
Withdrawal of suspected agent is the most important step in
management of DRESS. Culprit drug was withdrawn in every pa-
tients in our study, with 84.6% had their culprit drug withdrawn
within the ﬁrst day of hospitalization. Systemic corticosteroid has
been described as the treatment of choice. In our study, systemic
corticosteroid was administered in 57.7% of patients. However, the
number increased to 82.1% when considering only those who were
initially diagnosed with DRESS. Neither the differences in median
A. Hiransuthikul et al. / Allergology International 65 (2016) 432e438 437time of resolution period (12.5 versus 14.5 days, p ¼ 0.191) nor
mortality outcome (1 versus 1 case, p ¼ 0.438) between conser-
vative treatment (i.e. without the use of systemic corticosteroid)
and systemic corticosteroid were found in our study.
Two mortality cases were reported in our study. The ﬁrst case
was from fulminant liver failure due to omeprazole-induced DRESS.
Proton-pump inhibitors (PPI) have been reported to cause cuta-
neous reactions frequently, but usually mild in intensity. Only one
report of PPI-induced DRESS from Caboni et al. resulted from eso-
meprazole.35 However, to our knowledge, mortality due to PPI-
induced DRESS has not been reported before. Omeprazole was
withdrawn in the third day of hospitalization along with admin-
istration of systemic corticosteroid. The second case, which died
due to nosocomial infection, had her culprit drug (phenytoin)
withdrawn in the ﬁrst day of hospitalization. However, systemic
corticosteroid was not administered because of possible concurrent
infection. Unlike a previous study done in Taiwan which reported
pronounced eosinophilia in mortality cases compared to non-
mortality cases, eosinophilia was not signiﬁcantly different to
non-mortality cases (p ¼ 0.137).
Study limitations include a retrospective study and small
number of subjects. Despite small number of subjects, we began to
see some unique clinical features between each drug. To conﬁrm
and provide more useful clinical information for early detection
and improve the outcome of severe cutaneous adverse reactions
including DRESS is underway under The Registry of Severe Cuta-
neous Adverse Reactions in Thailand (ThaiSCAR).
In conclusion, phenytoin, nevirapine, allopurinol, and cotri-
moxazole are the major causes of DRESS. Allopurinol-induced
DRESS has the longest onset time also associated with higher
eosinophil level and higher incidence of renal involvement. The
mortality rate in this study was 4%. Thus, raising awareness among
both health care providers and public for early detection and
withdrawal of the suspected agent is the principal step in man-
agement of DRESS.
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